Clinical Trial Update: Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial of abetimus sodium (LJP 394) for lupus nephritis and systemic lupus erythematosus has completed, reporting on safety and efficacy findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Glomerulonephritis
• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• LJP 394 (Abetimus Sodium) (Abetimus Sodium)

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Immunologic Diseases, Autoimmune Diseases | Phase 3 | Status: COMPLETED